VERU INC. Unrealized Gain (Loss) on Derivatives
VERU INC. (VERU) reported Unrealized Gain (Loss) on Derivatives of $0 for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-08-10
- VERU INC. unrealized gain (loss) on derivatives for the quarter ending 2026-06-30 was $0.00.
- VERU INC. unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was $0.00.
- VERU INC. unrealized gain (loss) on derivatives for the quarter ending 2025-12-31 was $0.00.
- VERU INC. unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was $0.00.
- VERU INC. unrealized gain (loss) on derivatives for fiscal 2025 was -$3.14M.
- VERU INC. unrealized gain (loss) on derivatives for fiscal 2024 was -$239.00K, a 108.07% decline from fiscal 2023.
- VERU INC. unrealized gain (loss) on derivatives for fiscal 2023 was $2.96M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | $0.00 derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $0.00 derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | -$3.14M 10-K · filed 2025-12-17 |
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | -$3.14M 10-Q · filed 2026-08-10 | -$3.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$3.14M 10-Q · filed 2026-05-13 | -$3.48M derived: sum of 3 quarters · filed 2026-05-13 | -$3.40M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$3.14M 10-Q · filed 2026-02-11 | -$3.48M derived: sum of 2 quarters · filed 2026-02-11 | -$3.40M derived: sum of 3 quarters · filed 2026-02-11 | -$3.38M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | -$341.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$258.00K derived: sum of 2 quarters · filed 2025-12-17 | -$237.00K derived: sum of 3 quarters · filed 2025-12-17 | -$239.00K 10-K · filed 2025-12-17 |
| 2024-06-30 | $83.00K 10-Q · filed 2024-08-08 | $104.00K derived: sum of 2 quarters · filed 2025-05-08 | $102.00K 10-Q · filed 2025-08-12 | $746.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | $19.00K 10-Q · filed 2025-05-08 | $663.00K derived: sum of 3 quarters · filed 2025-05-08 | $2.45M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.00K 10-Q · filed 2025-02-13 | $642.00K derived: sum of 2 quarters · filed 2025-02-13 | $2.43M derived: sum of 3 quarters · filed 2025-02-13 | |
| 2023-09-30 | $644.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $2.43M derived: sum of 2 quarters · filed 2024-12-16 | $2.96M 10-K · filed 2024-12-16 | |
| 2023-06-30 | $1.79M 10-Q · filed 2024-08-08 | $2.32M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |